Veeva Systems Launched AI Tool for Clinical Trials
The new Study Builder tool uses generative AI to automate clinical trial configurations for life sciences firms.
Updated on Sept. 28, 2026 in Artificial Intelligence
Live Poll
Do you trust AI agents to manage complex clinical trial configurations and data?
Veeva Systems has developed an AI agent called Study Builder that leverages the Claude large language model to automate the configuration of electronic data capture forms and trial visit schedules. The technology, which is currently in an announced phase for future deployment, aims to streamline trial setup using established industry standards.
Why it matters
By automating the technical setup of trials, this tool seeks to minimize manual configuration errors and ensure greater compliance with trial protocols. It marks a push to integrate generative AI directly into the infrastructure used by pharmaceutical companies to manage clinical research data.
Study Builder functions as a software plugin running on the Claude large language model to configure systems from a single structured study definition. It utilizes the CDISC Unified Study Definitions Model to ensure consistency across the Veeva electronic data capture platform.
The players
Veeva Systems
A cloud computing company providing software stacks, data management, and operational platforms specifically for the global life sciences and pharmaceutical industries.
Anthropic
An AI research and deployment company that develops the Claude large language model, which is used here as the underlying engine for the Study Builder plugin.
The details
The technology ingests trial protocols to draft configuration settings across the Veeva electronic data capture (EDC) system—a digital platform for collecting patient trial data—and the Data Quality System. By reusing existing clinical research standards, the agent automates test data production while requiring human oversight to verify the output. The system is designed to work within the existing Veeva platform ecosystem, though its underlying model, Claude, remains restricted in mainland China.
Timeline
December 2026: Study Builder becomes available to existing platform licensees.
January 2027: Veeva is scheduled to release an additional agentic system for identifying pharmaceutical adverse events.
The Tech Race
This development extends the use of the CDISC Unified Study Definitions Model to automated configuration, following a clear industry shift toward standardized data structures in clinical trials. It positions Veeva against other enterprise platforms racing to replace manual trial setup with agentic workflows.
The tool will be available at no additional cost to existing Veeva EDC platform users when it launches. It is designed to change the workflow for trial coordinators by automating data form production, though it remains inaccessible for users located in mainland China due to model restrictions.
The takeaway
Veeva's move signifies that trial configuration, once a manual and error-prone hurdle, is becoming an automated function of existing data platforms. Observers should track the December 2026 deployment to see if the promised 24-hour configuration timeline holds up in large-scale clinical trials.
What happens next
Licensees can expect access to the Study Builder technology starting in December 2026. A separate agentic system for identifying pharmaceutical adverse events is scheduled for release in January 2027.
Further reading
For more on the integration of machine learning in research, visit the Artificial Intelligence section.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do you trust AI agents to manage complex clinical trial configurations and data?
